Expansion Therapeutics is a biotech startup that is seeking to complete a Series A financing round. This is the very first round of venture capital financing that a new company goes through.
They get money from either angel investors, early stage capital venture firms, or a combination of the two. Their goal is to fight a collection of genetic disorders which includes myotonic dystrophy type 1.
This genetic disorder is the main reason adults develop muscular dystrophy. They have so far raised about $53.3 million. Dr. Scott Rocklage of 5AM Ventures took part in this Series A.
There are a number of firms investing in Expansion Therapeutics. The four main venture capital firms were the aforementioned 5AM Ventures plus Novartis Venture Fund, Kleiner Perkins, and Sanofi Ventures. RA Capital Management and Alexandria Venture Investments also took a smaller role in this Series A financing round. Read more: Scott Rocklage | Bloomberg and Scott Rocklage | Crunchbase
Muscular dystrophy is believed to present itself when a person’s RNA reaches a toxic level. If the production of RNAs hit toxic levels in a person’s cells than myotonic dystrophy type 1 occurs.
At this point a number of organs and systems start to become defective such as the central nervous system, the hormonal system, the gastrointestinal system, the hearts, and muscles in general. It is a hereditary disease that is passed down through genetics. To date there is no cure for this condition.
Dr. Scott Rocklage is the managing partner at 5AM Ventures. He has years of experience in the healthcare industry as a researcher and developer, executive, and investor.
He attended the Berkeley campus of the University of California which is where he earned his chemistry degree. He then moved across the country and earned a Ph.D. in this subject at MIT.
Over the course of his professional career Dr. Scott Rocklage has published many research papers of which over 100 have been published in peer-reviewed scientific journals.
He also holds over 30 United States patents for which he either invented himself or co-invented with others. He now invests in early stage biotech startups and serves on many of these company’s board of directors.
Learn more about Scott Rocklage: